TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL

• Published in: PloS one Vol. 5; no. 1; p. e8620
• Main Authors: Lluis, Josep Maria, Nachbur, Ulrich, Cook, Wendy Diane, Gentle, Ian Edward, Moujalled, Donia, Moulin, Maryline, Wong, Wendy Wei-Lynn, Khan, Nufail, Chau, Diep, Callus, Bernard Andrew, Vince, James Edward, Silke, John, Vaux, David Lawrence
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science (PLoS) 08-01-2010
• Subjects: Animals; Base Sequence; CASP8 and FADD-Like Apoptosis Regulating Protein - biosynthesis; Caspase 8 - metabolism; Cell Survival - physiology; Cells, Cultured; DNA Primers; Fibroblasts - cytology; MAP Kinase Kinase Kinases - physiology; Mice; Mice, Knockout; NF-kappa B - physiology; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand - administration & dosage
• ISSN: 1932-6203
• DOI: 10.1371/journal.pone.0008620

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as a "death ligand"-a member of the TNF superfamily that binds to receptors bearing death domains. As well as causing apoptosis of certain types of tumor cells, TRAIL can activate both NF-kappaB and JNK signalling pathways. To determine the role of TGF-beta-Activated Kinase-1 (TAK1) in TRAIL signalling, we analyzed the effects of adding TRAIL to mouse embryonic fibroblasts (MEFs) derived from TAK1 conditional knockout mice. TAK1-/- MEFs were significantly more sensitive to killing by TRAIL than wild-type MEFs, and failed to activate NF-kappaB or JNK. Overexpression of IKK2-EE, a constitutive activator of NF-kappaB, protected TAK1-/- MEFs against TRAIL killing, suggesting that TAK1 activation of NF-kappaB is critical for the viability of cells treated with TRAIL. Consistent with this model, TRAIL failed to induce the survival genes cIAP2 and cFlipL in the absence of TAK1, whereas activation of NF-kappaB by IKK2-EE restored the levels of both proteins. Moreover, ectopic expression of cFlipL, but not cIAP2, in TAK1-/- MEFs strongly inhibited TRAIL-induced cell death. These results indicate that cells that survive TRAIL treatment may do so by activation of a TAK1-NF-kappaB pathway that drives expression of cFlipL, and suggest that TAK1 may be a good target for overcoming TRAIL resistance.